Back to search
FDAFDA · Food and drugs·Recall number D-0781-2022

Sermorelin Acetate 1 mg/mL (6 mL) Injection, 6 mL vials, Rx only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081

Published April 27, 2022 · Recall initiated: April 5, 2022

Summary

FDA records drug Class II recall D-0781-2022, published April 27, 2022 and initiated April 5, 2022. Recalling firm: North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding; Status: Terminated; Reported quantity: 76 vials; Lot: Lot #: 32963 BUD: 4/12/2022; 34824 BUD: 5/30/2022; 35130 BUD: 6/7/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
Distributor
Nationwide within United States
Lot
Lot #: 32963 BUD: 4/12/2022; 34824 BUD: 5/30/2022; 35130 BUD: 6/7/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Sermorelin Acetate 1 mg/mL (6 mL) Injection, 6 mL vials, Rx only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081 recalled?

Yes. FDA published recall D-0781-2022 on April 27, 2022. Reported hazard: Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

What should I do if I have this product?

Voluntary: Firm initiated · Letter